MedTrace Logo

Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies

NCT01846143 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-08-12

No results posted yet for this study

Summary

The purpose of this study is to learn what effects (good and bad) experimental phosphopeptide vaccines plus a tetanus peptide and other substances called polyICLC and Montanide ISA-51 have on people with melanoma. The investigators will also look at whether the experimental reagents cause any changes in the immune system.

Conditions

Interventions

BIOLOGICAL

pBCAR3-phosphopeptide

BIOLOGICAL

pIRS2-phosphopeptide

BIOLOGICAL

2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)

Sponsors & Collaborators

  • Craig L Slingluff, Jr

    lead OTHER

Principal Investigators

  • Victor Engelhard, PhD · University of Virginia

  • Craig L. Slingluff, Jr., MD · University of Virginia

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2015-06-30
Completion
2015-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01846143 on ClinicalTrials.gov